Is compounded semaglutide legal in 2026?

Compounding semaglutide from bulk drug substance at an outsourcing facility is not permitted, because both of the statutory conditions that would allow it are unmet. FDA states that outsourcing facilities are restricted from compounding with a bulk drug substance unless the substance appears on the 503B bulks list, or the drug compounded from it is on FDA's drug shortage list at the time of compounding, distribution and dispensing — and that, as of 1 April 2026, 'Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list.' The shortage listing is what the compounded-GLP-1 industry was built on and it closed: FDA determined on 21 February 2025 that the shortage of semaglutide injection products was resolved. The wind-down for state-licensed pharmacies and physicians compounding under section 503A ran, in FDA's own words, 'until April 22, 2025, or until the date of the district court's decision on the plaintiffs' forthcoming preliminary injunction motion in Outsourcing Facilities Association (OFA) v. FDA, 4:25-cv-00174 (N.D. Tex.), whichever is later' — the court denied that motion on 24 April 2025, so the 503A period ran to 24 April 2025, not 22 April. For outsourcing facilities under section 503B it ran to 22 May 2025. FDA states that for 503A compounding the period of enforcement discretion 'has ended'. Semaglutide is a component of FDA-approved drugs, so this is not a blanket prohibition on every form of compounding — but a compounded product that duplicates an approved one runs into the separate 'essentially a copy' restriction, which requires a prescriber to determine and document a significant difference for an identified individual patient.

Is Ozempic approved for weight loss?

No. Every indication in the FDA-approved labeling for Ozempic (semaglutide injection, NDA 209637) is restricted to adults with type 2 diabetes mellitus: improving glycemic control as an adjunct to diet and exercise; reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Weight loss is not among them. Prescribing Ozempic for weight loss in a patient without type 2 diabetes is off-label use, which is a decision for a licensed prescriber and is not something this label supports. Note also that 'Ozempic' names products under two different applications — the injection under NDA 209637 described here, and the tablets under NDA 213051, whose own label is likewise confined to adults with type 2 diabetes mellitus.

Can I use Wegovy instead of Ozempic if I have type 2 diabetes?

Not on the strength of the label. The two are the same molecule from the same sponsor, but their approvals are not interchangeable, and the direction people rarely check is this one: FDA has stated that 'Wegovy and Wegovy HD, the approved formulations that do not contain propylene glycol, have not been shown to be safe and effective for the treatment of type 2 diabetes.' FDA made that statement in its 503B notice while noting that the semaglutide products approved for subcutaneous injection — Ozempic, Wegovy and Wegovy HD — 'have differing concentrations and labeled indications'. So the non-interchangeability runs both ways: Ozempic carries no weight-management indication, and Wegovy carries no type 2 diabetes indication. Read the appositive in FDA's sentence too, because it is doing work — the formulations FDA is describing are the propylene-glycol-free ones, which is the same distinction the 'PG-free' compounding pitch turns on.

Is semaglutide sold as a research peptide the same thing as Ozempic or Wegovy?

No. FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that were 'falsely labeled "for research purposes" or "not for human consumption"', noting that these products have been sold directly to consumers for human use with dosing instructions. Read FDA's verb: falsely labeled. FDA does not treat the research wording as a disclaimer that changes what the product is — it treats it as a false statement about it, and characterises the sale as illegal notwithstanding the wording on the vial. FDA's stated tell is the conduct: a product shipped to consumers with instructions for human use is not being sold for research. The approval, the labels and the outcome trials behind the approved products describe those products, and an unapproved vial sits outside all three.

Is semaglutide sodium or semaglutide acetate the same drug as the approved semaglutide?

No — FDA's position is that they are a DIFFERENT ACTIVE INGREDIENT, not a lower grade of the same one. FDA received reports that in some cases compounders may be using salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, and stated: 'The salt forms are different active ingredients than is used in the approved drugs, which contain the base form of semaglutide. The FDA is not aware of any basis for compounding using the salt forms that would meet the FD&C Act conditions for types of active ingredients that can be used in compounding.' That distinction is what a vial labelled simply 'semaglutide' hides. If the contents are a salt form, the approval, the prescribing information and the outcome trials behind the approved products are not describing what is in the vial — those studied the base form. FDA has since restated the position in different words, saying it does 'not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug' and is 'not aware of any lawful basis for their use in compounding' — that later wording is on FDA's GLP-1 concerns page, not on the alert quoted here.

Did FDA find that compounded semaglutide doesn't work?

No — FDA never reached that question, and says so explicitly. FDA's clinical-need analysis under section 503B is sequential, and its evaluation of semaglutide stopped at the threshold: 'Because this nomination did not pass through Part 1(a), we did not reach Part 2 and therefore did not consider the Part 2 factors, including the available evidence of effectiveness or lack of effectiveness of a drug product compounded with semaglutide.' What FDA actually evaluated was narrow — whether the nominations identified an attribute of the FDA-approved semaglutide products that makes them medically unsuitable for identified patients, such that a compounded product is needed to address it. It found they did not, and on that basis tentatively found no clinical need and proposed not to include semaglutide on the 503B Bulks List. So FDA's proposal is not a verdict that compounded semaglutide is ineffective, and equally the absence of such a verdict is not evidence that it works. On this record FDA has expressed no view either way.

Is compounded semaglutide safe?

Compounded semaglutide is not an FDA-approved drug, which means FDA does not review it for safety, effectiveness or quality before it is marketed, and FDA has published specific documented concerns about it. As of 31 May 2026 FDA had received 990 reports of adverse events associated with compounded semaglutide; FDA notes many of these appear consistent with adverse events seen with the approved products, that causation cannot always be determined, and that because federal law does not require non-outsourcing-facility pharmacies to report adverse events, the true number is likely underreported. Separately, FDA has received reports of adverse events, some requiring hospitalization, that may be related to overdoses from dosing errors with compounded injectable semaglutide, which it attributes to patients measuring and self-administering incorrect amounts and to health care professionals miscalculating — the approved products are pens delivering a preset amount, while compounded products are supplied as vials and syringes. FDA has also reported fraudulent compounded semaglutide whose labels name compounding pharmacies that do not exist. Note the shape of these findings: they concern the product and its presentation, not semaglutide the molecule, whose own labeled risks — including a boxed warning for thyroid C-cell tumors — apply regardless.

Semaglutide

Name: Semaglutide
Published: 2026-07-16

Also sold as: Ozempic, Wegovy, Wegovy HD, Rybelsus, NN9535, semaglutide sodium, semaglutide acetate

Semaglutide is the active ingredient in drug products approved under four FDA new drug applications, all from Novo Nordisk — Ozempic injection (NDA 209637), Rybelsus and Ozempic tablets (NDA 213051), Wegovy and Wegovy HD injection (NDA 215256) and Wegovy tablets (NDA 218316). Every one of the four carries a boxed warning for risk of thyroid C-cell tumors, and their approved indications vary by product, running across type 2 diabetes, cardiovascular risk reduction, kidney outcomes in type 2 diabetes, weight management and MASH — no single product carries them all. That approval describes the approved products only. It does not extend to compounded semaglutide, to semaglutide salt forms — which FDA states are 'different active ingredients than is used in the approved drugs, which contain the base form of semaglutide' — or to vials falsely labelled 'for research purposes'. FDA has stated that semaglutide appears neither on the 503B bulks list nor on its drug shortage list, and tentatively found no clinical need for outsourcing facilities to compound with it — but that was a threshold finding, and FDA states it never reached the question of the effectiveness or lack of effectiveness of compounded semaglutide. FDA had received 990 reports of adverse events associated with compounded semaglutide as of 31 May 2026, a count it says is likely underreported, that it cannot always attribute to the drug, and many of which appear consistent with adverse events related to the approved versions.

Which molecule this is. A glucagon-like peptide-1 (GLP-1) receptor agonist. The disambiguation that matters here is not sequence but SALT FORM. FDA's approved products contain the BASE form of semaglutide. FDA has stated it received reports that compounders may be using semaglutide sodium and semaglutide acetate, and that — verbatim — 'The salt forms are different active ingredients than is used in the approved drugs, which contain the base form of semaglutide.' A vial labelled 'semaglutide' is therefore not necessarily the substance the approved products' trials studied. The aliases above list the salt forms because they are sold under this name, not because they are the same drug.

FDA status

FDA-approved

FDA has approved this as a drug. Approval is always for a specific indication and a specific population — check which one, because it is frequently not the use it is marketed for.

FDA-approved. Approval is always for a specific indication and population — see the approval record below, because it is routinely not the use this is marketed for.

List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act — FDA, 1 May 2026

“Semaglutide is an active ingredient in FDA-approved drug products: 2 mg/3 mL, 4 mg/3 mL, and 8 mg/3 mL solutions for subcutaneous (SC) injection which contain propylene glycol (Ozempic, NDA 209637); … (Wegovy and Wegovy HD, NDA 215256); … oral tablets (Wegovy, NDA 218316); and … oral tablets (Rybelsus and Ozempic, NDA 213051).”

Checked against the source on 16 July 2026.

Evidence

Proven in humans

Efficacy established by adequate, well-controlled trials in humans.

Administration check RUN, not assumed. SELECT (NCT03574597) was opened and read on 2026-07-16: intervention type DRUG, semaglutide administered subcutaneously versus placebo, Phase 3, enrolment 17,604 ACTUAL, lead sponsor Novo Nordisk A/S, status COMPLETED (primary completion 2023-06-21 ACTUAL; completion 2023-06-29 ACTUAL; results first posted 2024-08-30), hasResults true. The `date` field above carries the primary completion date. Semaglutide was ADMINISTERED to humans — it was not measured as an endogenous biomarker, which is the trap that reduces MOTS-c and TB-500 from an apparent five human RCTs to an actual zero. Independently corroborated against section 14.1 of the FDA-approved WEGOVY label, which describes the same trial. This registration is also clean of the contamination in this vertical: it is not a Hudson Biotech registration, not a February-2026 recruiting shell, and not a relabelled clone. SCOPE — the tier attaches to the approved indications and to the approved base-form products, and to nothing else. It does not transfer to salt forms, to compounded combinations, or to indications outside the label. A large trial of one product is not evidence for a different product sold under the same name.

SELECT — Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity — ClinicalTrials.gov, 21 June 2023Checked against the source on 16 July 2026.

What FDA actually approved

Application: NDA 209637 (Ozempic injection); NDA 213051 (Rybelsus and Ozempic tablets); NDA 215256 (Wegovy and Wegovy HD injection); NDA 218316 (Wegovy tablets) — Ozempic, Wegovy, Wegovy HD, Rybelsus
Approved indication: WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. • To reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity. o Adults with overweight in the presence of at least one weight-related comorbid condition. • For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis. — WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • To reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. • To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.

Verbatim from the label covering NDA 215256 (injection) and NDA 218316 (tablets) — one document covers both. THIS FIELD DOES NOT COVER ALL FOUR NDAs: Ozempic injection (NDA 209637) and Rybelsus/Ozempic tablets (NDA 213051) carry DIFFERENT, diabetes-scoped indications, each recorded verbatim under fdaFindings against its own label. Three things worth reading precisely. (1) Every indication above is conditioned on 'in combination with a reduced calorie diet and increased physical activity' — the label does not approve it as a standalone. (2) The MASH indication is ACCELERATED approval on a surrogate; the label states continued approval 'may be contingent upon the verification and description of clinical benefit in a confirmatory trial'. Accelerated approval is not the same evidentiary standing as the CV outcomes indication, and collapsing the two is a real misreading. (3) One product is discontinued — an Ozempic presentation under NDA 209637, per Drugs@FDA — but semaglutide as a franchise is marketed, so `discontinued` is false. GAP: Drugs@FDA shows later approved supplements to NDA 215256 (SUPPL 31, 2026-05-05; SUPPL 25, 2026-06-18) than the s029 label read here. The indications above are verbatim as of 2026-03-23 and may not reflect those supplements. Re-check before relying on completeness.

WEGOVY (semaglutide) injection / tablets — Highlights of Prescribing Information — FDA, 23 March 2026Checked against the source on 16 July 2026.

What FDA found

FDA’s own words. These are the most citable thing on this site, and the least likely to appear anywhere funded by someone selling the compound.

FDA tentatively finds no basis to conclude there is a clinical need for an outsourcing facility to compound using semaglutide, and proposes not to include it on the 503B Bulks List.
Two distinctions the coverage collapses. This is 503B (outsourcing facilities), NOT the 503A bulks list that BPC-157 and the consumer peptides sit against — different statute, different list, different test. And it is a TENTATIVE finding in a proposed notice, not a final determination; the comment period closed 2026-06-30. What FDA actually evaluated is narrow and specific: whether the approved products are MEDICALLY UNSUITABLE for identified patients. It found the nominations did not identify any such unsuitability.
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act — FDA, 1 May 2026
“FDA tentatively finds no basis to conclude that there is a clinical need for an outsourcing facility to compound using the following bulk drug substances: semaglutide, tirzepatide, and liraglutide. Therefore, we propose not to include these bulk drug substances on the 503B Bulks List.”
Checked against the source on 16 July 2026.
OZEMPIC (NDA 209637) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease; to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Recorded verbatim because the brand-name gap is the whole point. EVERY Ozempic indication is gated on 'adults with type 2 diabetes mellitus'. Ozempic is not approved for weight management in patients without type 2 diabetes — Wegovy is the semaglutide product with the obesity indications. FDA itself flags the asymmetry in the 503B notice, whose sentence is quoted in full because the appositive is load-bearing: 'Wegovy and Wegovy HD, the approved formulations that do not contain propylene glycol, have not been shown to be safe and effective for the treatment of type 2 diabetes.' Same molecule, same sponsor, non-interchangeable approvals in both directions. That sentence is NOT in this field's source — it is in the Federal Register notice, and it is cited to that document in the FAQ that turns on it.
OZEMPIC (semaglutide) injection — Highlights of Prescribing Information (SPL) — FDA, 14 October 2025Checked against the source on 16 July 2026.
RYBELSUS and OZEMPIC tablets (NDA 213051) are indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
The fourth NDA, recorded verbatim so that the record's own four-NDA framing is carried by four sourced labels rather than three. Read the gating: both indications are confined to 'adults with type 2 diabetes mellitus', and the CV indication is narrower still — it requires patients 'at high risk for these events', where Wegovy's CV indication requires established CV disease with obesity or overweight. Note the brand-name collision this label documents: OZEMPIC is a brand name under TWO different NDAs — the injection (NDA 209637) and the tablets shipped under this one. 'Ozempic' does not identify a product.
RYBELSUS and OZEMPIC (semaglutide) tablets — Highlights of Prescribing Information (SPL) — FDA, 30 January 2026
“RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.”
Checked against the source on 16 July 2026.
FDA has stated that semaglutide salt forms — semaglutide sodium and semaglutide acetate — are different active ingredients than the base form used in the approved drugs, and that it is not aware of any basis for compounding with them that would meet the FD&C Act conditions for active ingredients that can be used in compounding.
The single most load-bearing sentence for anyone buying something labelled 'semaglutide' that is not an approved product. FDA is not saying the salt is a lower-grade semaglutide. It is saying it is a DIFFERENT ACTIVE INGREDIENT — which means the approval, the label and the trials behind them do not describe it. Note this page is stale in one respect: it states 'three FDA-approved semaglutide products', which was true on 2024-07-26 and is not true now (four NDAs). The salt-form finding is unaffected.
FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products — FDA, 26 July 2024
“The salt forms are different active ingredients than is used in the approved drugs, which contain the base form of semaglutide. The FDA is not aware of any basis for compounding using the salt forms that would meet the FD&C Act conditions for types of active ingredients that can be used in compounding.”
Checked against the source on 16 July 2026.
FDA has stated it may consider a compounded drug product combining semaglutide API with another API, such as vitamin B12 (cyanocobalamin), to be essentially a copy of a commercially available drug product.
Names the exact product the compounding market built to argue it was NOT making copies. The 'significant difference' escape requires a prescriber to determine and document a significant difference for an identified individual patient — a per-patient finding, not a product design. Adding B12 to a formulation is not, by itself, that finding.
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — FDA, 1 April 2026Checked against the source on 16 July 2026.
In a published phase 2 trial cited by a nominator (NCT05486065, Aroda et al. 2025), FDA reported a MIXED result. Neither higher-dose semaglutide arm demonstrated a statistically significant improvement in glycemic control (HbA1c) compared with the lower-dose arm using the treatment policy estimand. On body weight, the highest-dose arm DID show a statistically significant decrease versus the lower-dose arm using that estimand, while the intermediate-dose arm did not. Adverse events and treatment discontinuations due to adverse events were more frequent in both higher-dose arms than in the lower-dose arm.
This one runs BACKWARDS to the market's premise, which is why it is here — but it must be read as the mixed result it is, not as a clean negative. A nominator cited this trial while it was unpublished, to argue that higher doses than the approved products allow have a 'superior effect' and that compounding was therefore needed to supply them. It published. The nominator's argument was about medical unsuitability of the approved products, and FDA's characterisation of the published result is blunt: the results 'do not support the nominator's argument'. Read precisely: the one endpoint that did separate was body weight, and only at the highest dose — the intermediate dose did not separate on either endpoint, so the trial does not describe a dose-response the more-is-better case needs. Both higher arms carried more adverse events and more discontinuations. A single significant weight endpoint in a phase 2 trial is not a finding that the approved products fail to achieve their intended clinical benefit, which is the question FDA was answering. QUOTE HANDLING: the Federal Register names the specific milligram strengths of each arm. They are replaced above with bracketed descriptors ([highest], [intermediate], [lowest]) under this site's no-dosing policy — a dose-to-outcome mapping is the actionable part for someone self-administering an unapproved vial. Nothing else in the quote is altered, and no finding depends on the elided figures.
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act — FDA, 1 May 2026
“The results do not support the nominator's argument. … The study did not demonstrate a statistically significant improvement in glycemic control (as measured by hemoglobin A1c) … using the treatment policy estimand. There was a statistically significant decrease in body weight when the semaglutide [highest] dose was compared to the [lowest] dose using the treatment policy estimand, but the study did not demonstrate a statistically significant decrease in body weight when the [intermediate] dose was compared to the [lowest] dose. We note that adverse events and treatment discontinuations due to adverse events were more frequent in the [two higher] groups than in the [lowest] dose group.”
Checked against the source on 16 July 2026.
FDA has stated that neither semaglutide nor tirzepatide currently appears on the 503B bulks list or on FDA's drug shortage list, and that outsourcing facilities are restricted from compounding with a bulk drug substance unless it appears on the 503B bulks list or the drug compounded from it is on FDA's drug shortage list at the time of compounding, distribution and dispensing.
The two-sentence answer to 'is compounded semaglutide legal', and the reason the market's 2023-2024 arrangement no longer exists. Read the mechanism, not the vibe. Both statutory doors for 503B compounding are conditional, and FDA states both conditions are now unmet: semaglutide is not on the 503B bulks list (it was evaluated and FDA proposed not to add it — see the tentative finding above), and it is not on the shortage list (FDA determined on 2025-02-21 that the shortage of semaglutide injection products was resolved, having confirmed with the manufacturer that stated availability and manufacturing capacity could meet present and projected national demand). The shortage listing is what the entire compounded-GLP-1 telehealth industry was built on, and it is what closed. TIMELINE, because the dates are load-bearing and are widely misreported — including by this record until it was corrected. FDA's 503A wind-down was NOT a fixed 2025-04-22 deadline: FDA wrote that it did not intend to act against a 503A pharmacy or physician 'until April 22, 2025, or until the date of the district court's decision on the plaintiffs' forthcoming preliminary injunction motion in Outsourcing Facilities Association (OFA) v. FDA, 4:25-cv-00174 (N.D. Tex.), whichever is later'. The court denied that motion on 2025-04-24, which was later, so the 503A period ran to 2025-04-24. The 503B period ran to 2025-05-22, unaffected because that date postdates the decision. FDA then stated that for 503A pharmacies and physicians the period of enforcement discretion 'has ended'. This did not go the compounders' way and it is not still pending. SCOPE: this finding is about compounding from BULK semaglutide. It is not a statement that no lawful compounding of any kind can occur, and it is not a criminal-law statement.
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — FDA, 1 April 2026
“Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list.”
Checked against the source on 16 July 2026.
FDA did not evaluate whether compounded semaglutide is effective. FDA stated that because the nomination did not pass through Part 1(a) of its clinical-need analysis, it did not reach Part 2 and therefore did not consider the Part 2 factors, including the available evidence of effectiveness or lack of effectiveness of a drug product compounded with semaglutide.
Recorded because it is the finding that cuts BOTH ways, and both misreadings are live. Sellers read FDA's silence as an absence of adverse findings; critics read FDA's proposal as a determination that compounded semaglutide does not work. Neither is what happened. FDA's clinical-need test is sequential: Part 1(a) asks the threshold question of whether the nomination identifies an attribute of the approved drug making it medically unsuitable for identified patients. The nomination failed there, so the analysis stopped there, and the effectiveness question was never opened. On this record FDA has expressed no view on whether compounded semaglutide works. That is a genuine blank, and this site records blanks rather than filling them.
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act — FDA, 1 May 2026
“Because this nomination did not pass through Part 1(a), we did not reach Part 2 and therefore did not consider the Part 2 factors, including the available evidence of effectiveness or lack of effectiveness of a drug product compounded with semaglutide.”
Checked against the source on 16 July 2026.
On nominations to compound semaglutide for sublingual and buccal administration, FDA stated that the nominators referred to concerns about oral routes of administration generally and did not identify any unsuitability with the approved semaglutide products, nor explain why the injectable products would be medically unsuitable for patients who cannot swallow a tablet.
Directly on point for sublingual and 'oral drop' semaglutide, which is sold as an established alternative to injection. It was nominated as one, and it was evaluated: FDA recorded that semaglutide was nominated for the subcutaneous, sublingual, buccal and oral routes. Note what FDA does NOT do here — it does not dispute that dysphagia is real or that compounding serves patients who cannot swallow tablets. It concedes both. The failure is one of specificity: a general concern about swallowing is not a finding about THESE products, one of which is an injection. The single paper the nominator offered was characterised by its own authors as a guideline for future investigators, and FDA noted the authors 'did not design their study to assess, and, accordingly, do not identify, any medical unsuitability of FDA-approved GLP-1 receptor agonists' and that the paper discusses GLP-1 drugs generally rather than the approved semaglutide products.
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act — FDA, 1 May 2026
“While we have no reason to disagree with the proposition that difficulty swallowing is a "well-documented issue" and that compounded drugs can serve an important need for patients who cannot swallow tablets, the nominators refer to concerns about oral routes of administration generally; they do not identify any unsuitability with approved semaglutide products. Nor do they explain why the injectable drug products would be medically unsuitable for patients who cannot swallow a tablet.”
Checked against the source on 16 July 2026.
On the claim that some patients are 'hyper-responders' who need strengths other than those commercially available, FDA reported that the nominator provided no reference supporting its statement that 5-15% of the population are hyper-responders, and that the study the nominator cited (Wilding et al. 2021) does not mention 'hyper-responders' or the 5-15% statistic at all.
This is FDA opening the citation and finding it does not say what it was cited for — the same failure mode this site exists to correct, caught here by the regulator, in a filing, against a party with counsel. The 'hyper-responder' concept is a load-bearing premise of personalised-GLP-1 marketing. FDA also recorded that the nominators did not explain why a patient needing a lower maintenance strength could not use one of the approved products that contain a lower concentration, and did not explain why a slower escalation using the approved products could not be used in patients who do not tolerate escalation. The specific figures in FDA's reasoning are elided here under this site's no-dosing policy; no finding depends on them.
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act — FDA, 1 May 2026
“The nominator provides no reference that supports its statement about what "has been estimated." The nominator cites Wilding et al. (2021), which does not mention "hyper-responders" or the 5-15% statistic (Ref. 3).”
Checked against the source on 16 July 2026.
FDA stated it has not identified any data or information to suggest that propylene glycol would cause a drug product containing semaglutide to be medically unsuitable, and noted that the approved propylene-glycol-free formulations of Wegovy and Wegovy HD are themselves labeled for injection site reactions.
The 'preservative-free / PG-free' compounded pitch, evaluated and not sustained. FDA's reasoning is worth reading because it is empirical rather than dismissive: injection site reaction is reported in trials of injectable therapeutics not formulated with propylene glycol at all, including insulins and other GLP-1 receptor agonists; the approved PG-free semaglutide products carry the same labeled reaction. FDA noted that 'the presence of propylene glycol in Ozempic and the absence of this excipient in Wegovy suggests that determinants of injection site reactions are likely more complex than the inclusion or exclusion of propylene glycol in the formulation'. The one FAERS report FDA discussed involved a patient with a history of severe propylene glycol allergy, and FDA's assessment was that 'It is unclear whether the reaction experienced can be attributed to propylene glycol'. Crucially, FDA added that even if PG-containing formulations were unsuitable for some patients, the nominator gave no basis to conclude those patients could not use the approved products that are PG-free — an approved product already answers the stated need.
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act — FDA, 1 May 2026
“FDA has not identified any data or information to suggest that propylene glycol would cause a drug product containing semaglutide to be medically unsuitable.”
Checked against the source on 16 July 2026.
FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that were falsely labeled 'for research purposes' or 'not for human consumption', stating these products have been sold directly to consumers for human use with dosing instructions.
The research-label theory, addressed by FDA on the compound where the most money rides on it. Note FDA's verb: 'falsely labeled'. The label is not treated as a disclaimer that changes what the product is — it is treated as a false statement about it, and the sale is characterised as illegal notwithstanding the wording on the vial. FDA's stated tell is that the products ship to consumers with dosing instructions, which is conduct inconsistent with the label the seller chose. This is the same failed theory FDA has held against twice elsewhere in 2026; semaglutide is simply where it is most lucrative.
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA, 15 June 2026
“FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that are falsely labeled "for research purposes" or "not for human consumption." These products have been sold directly to consumers for human use with dosing instructions.”
Checked against the source on 16 July 2026.
Semaglutide appears in none of Categories 1, 2 or 3 of the 503A bulk drug substances list updated 2026-05-14.
Recorded to close a misreading, not to assert a status. Verified by fetching and text-extracting the document directly: no hit for 'semaglutide' anywhere. This absence means something entirely different from BPC-157's absence. BPC-157 was nominated and left Category 2 when the nominators withdrew. Semaglutide was never in this system at all — a 503A bulks nomination is a route for substances WITHOUT an approved product, and semaglutide has four. Categorical silence here is neither permission nor a safety finding.
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026Checked against the source on 16 July 2026.

Documented safety signals

Boxed warning — risk of thyroid C-cell tumors. In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether it causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. Contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
FDA's highest-level warning, and it sits on the most-prescribed peptide in the country. This entry covers NDA 215256 and NDA 218316 only, which is what its source covers. The other two NDAs carry the same boxed warning and are recorded separately below, against their own labels — the quickAnswer says every one of the four applications carries it, and a claim about four labels needs four labels. The contraindication is a screening question a purchaser of an unapproved product is never asked, because there is no label to ask it.
WEGOVY (semaglutide) injection / tablets — Highlights of Prescribing Information — FDA, 23 March 2026
“In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.”
Checked against the source on 16 July 2026.
Boxed warning — risk of thyroid C-cell tumors, on OZEMPIC injection (NDA 209637). In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
Recorded as its own sourced entry rather than left as an aside inside another entry's note, which is where it previously lived. Note the wording this label carries that the Wegovy label does not: 'dose-dependent and treatment-duration-dependent'.
OZEMPIC (semaglutide) injection — Highlights of Prescribing Information (SPL) — FDA, 14 October 2025
“In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.”
Checked against the source on 16 July 2026.
Boxed warning — risk of thyroid C-cell tumors, on RYBELSUS and OZEMPIC tablets (NDA 213051). In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
The fourth NDA's boxed warning, previously unsourced anywhere on this record. Worth recording on its own because it defeats the intuition the oral route invites: these are tablets, not injections, and they carry the identical boxed warning and the identical MTC and MEN 2 contraindication. Route of administration is not the risk axis here.
RYBELSUS and OZEMPIC (semaglutide) tablets — Highlights of Prescribing Information (SPL) — FDA, 30 January 2026
“In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.”
Checked against the source on 16 July 2026.
FDA has received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products.
The harm here is not the molecule — it is the presentation. FDA attributes the errors to patients measuring and self-administering incorrect amounts and to providers miscalculating, noting that many patients receiving vials 'lacked experience with self-injections' and that 'confusion between different units of measurement (e.g., milliliters, milligrams and "units")' may have contributed. The approved products are pens delivering a preset amount; the compounded products are vials and syringes. FDA also notes a prolonged period of observation may be necessary given semaglutide's long half-life of about one week. This is the clearest case on the site that the same verified molecule is not the same risk once it leaves the approved product.
FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products — FDA, 26 July 2024
“FDA has received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products.”
Checked against the source on 16 July 2026.
Labeled warnings and precautions include acute pancreatitis, acute gallbladder disease, hypoglycemia (with concomitant insulin or insulin secretagogue), acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions including anaphylaxis and angioedema reported postmarketing, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation.
Reproduced because 'well-tolerated' is doing heavy lifting in the marketing. Most common adverse reactions at incidence 5% or greater in adults or paediatric patients aged 12 and older, per the label: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss.
WEGOVY (semaglutide) injection / tablets — Highlights of Prescribing Information — FDA, 23 March 2026Checked against the source on 16 July 2026.
As of 31 May 2026, FDA had received 990 reports of adverse events associated with compounded semaglutide. FDA attaches three qualifications to that count. It states that federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA, so it is likely that adverse events from compounded versions of these drugs are underreported; that many of the adverse events reported for compounded products appear to be consistent with adverse events related to the FDA-approved versions of these products; and that it is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed.
The only hard count FDA publishes on compounded semaglutide, and the only place on this site where a compound has one. It must be read with all three of FDA's own caveats attached, or it becomes propaganda in either direction. (1) FDA states 'It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed' — 990 reports is not 990 injuries caused. (2) FDA states many of the adverse events reported for compounded products 'appear to be consistent with adverse events related to the FDA-approved versions' — much of this is the drug behaving as the label says it behaves, not a compounding-specific harm. (3) The underreporting point above is structural and cuts the other way: the reporting duty that generates these numbers does not reach the pharmacies dispensing most of this product, so 990 is a floor of unknown height, not a rate. A denominator does not exist. Anyone quoting this number as a risk rate is inventing the part that matters. The comparable figure for compounded tirzepatide was more than 730.
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA, 15 June 2026
“FDA has received reports of adverse events related to compounded versions of semaglutide and tirzepatide. However, federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported. Many of the adverse events reported for compounded products appear to be consistent with adverse events related to the FDA-approved versions of these products. As of May 31, 2026, the FDA has received: 990 reports of adverse events associated with compounded semaglutide. … It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events.”
Checked against the source on 16 July 2026.
FDA has stated it is aware of fraudulent compounded semaglutide marketed in the U.S. that contains false information on the product label — in some cases the compounding pharmacies identified on the labels do not exist, and in other cases the labels name a licensed pharmacy that, based on information FDA gathered, did not compound the products.
The signal that defeats the standard consumer check. The advice everywhere is to verify the compounding pharmacy on the label; FDA is reporting that the pharmacy on the label is sometimes fictional, and sometimes a real pharmacy that had nothing to do with the vial. A label naming a pharmacy that does exist is therefore not evidence that pharmacy made it. FDA has also established a green list import alert (66-80) directed at GLP-1 active pharmaceutical ingredients with potential quality concerns, and separately warns of counterfeit Ozempic in the U.S. drug supply chain. This is a supply-chain finding, not a pharmacology finding: it says nothing about semaglutide the molecule and everything about what is in an unverifiable vial.
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA, 15 June 2026
“FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label. In some cases, the compounding pharmacies identified on the labels of the products do not exist.”
Checked against the source on 16 July 2026.

Questions people actually ask

Every answer cites the document behind it. Where the honest answer is “nobody knows”, that is the answer you will get.

Is compounded semaglutide legal in 2026?: Compounding semaglutide from bulk drug substance at an outsourcing facility is not permitted, because both of the statutory conditions that would allow it are unmet. FDA states that outsourcing facilities are restricted from compounding with a bulk drug substance unless the substance appears on the 503B bulks list, or the drug compounded from it is on FDA's drug shortage list at the time of compounding, distribution and dispensing — and that, as of 1 April 2026, 'Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list.' The shortage listing is what the compounded-GLP-1 industry was built on and it closed: FDA determined on 21 February 2025 that the shortage of semaglutide injection products was resolved. The wind-down for state-licensed pharmacies and physicians compounding under section 503A ran, in FDA's own words, 'until April 22, 2025, or until the date of the district court's decision on the plaintiffs' forthcoming preliminary injunction motion in Outsourcing Facilities Association (OFA) v. FDA, 4:25-cv-00174 (N.D. Tex.), whichever is later' — the court denied that motion on 24 April 2025, so the 503A period ran to 24 April 2025, not 22 April. For outsourcing facilities under section 503B it ran to 22 May 2025. FDA states that for 503A compounding the period of enforcement discretion 'has ended'. Semaglutide is a component of FDA-approved drugs, so this is not a blanket prohibition on every form of compounding — but a compounded product that duplicates an approved one runs into the separate 'essentially a copy' restriction, which requires a prescriber to determine and document a significant difference for an identified individual patient.
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — FDA, 1 April 2026
“Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list.”
Checked against the source on 16 July 2026.
Is Ozempic approved for weight loss?: No. Every indication in the FDA-approved labeling for Ozempic (semaglutide injection, NDA 209637) is restricted to adults with type 2 diabetes mellitus: improving glycemic control as an adjunct to diet and exercise; reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Weight loss is not among them. Prescribing Ozempic for weight loss in a patient without type 2 diabetes is off-label use, which is a decision for a licensed prescriber and is not something this label supports. Note also that 'Ozempic' names products under two different applications — the injection under NDA 209637 described here, and the tablets under NDA 213051, whose own label is likewise confined to adults with type 2 diabetes mellitus.
OZEMPIC (semaglutide) injection — Highlights of Prescribing Information (SPL) — FDA, 14 October 2025
“OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.”
Checked against the source on 16 July 2026.
Can I use Wegovy instead of Ozempic if I have type 2 diabetes?: Not on the strength of the label. The two are the same molecule from the same sponsor, but their approvals are not interchangeable, and the direction people rarely check is this one: FDA has stated that 'Wegovy and Wegovy HD, the approved formulations that do not contain propylene glycol, have not been shown to be safe and effective for the treatment of type 2 diabetes.' FDA made that statement in its 503B notice while noting that the semaglutide products approved for subcutaneous injection — Ozempic, Wegovy and Wegovy HD — 'have differing concentrations and labeled indications'. So the non-interchangeability runs both ways: Ozempic carries no weight-management indication, and Wegovy carries no type 2 diabetes indication. Read the appositive in FDA's sentence too, because it is doing work — the formulations FDA is describing are the propylene-glycol-free ones, which is the same distinction the 'PG-free' compounding pitch turns on.
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act — FDA, 1 May 2026
“We note that the semaglutide drug products approved for use as an SC injection (i.e., Ozempic, Wegovy, Wegovy HD) have differing concentrations and labeled indications. Wegovy and Wegovy HD, the approved formulations that do not contain propylene glycol, have not been shown to be safe and effective for the treatment of type 2 diabetes.”
Checked against the source on 16 July 2026.
Is semaglutide sold as a research peptide the same thing as Ozempic or Wegovy?: No. FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that were 'falsely labeled "for research purposes" or "not for human consumption"', noting that these products have been sold directly to consumers for human use with dosing instructions. Read FDA's verb: falsely labeled. FDA does not treat the research wording as a disclaimer that changes what the product is — it treats it as a false statement about it, and characterises the sale as illegal notwithstanding the wording on the vial. FDA's stated tell is the conduct: a product shipped to consumers with instructions for human use is not being sold for research. The approval, the labels and the outcome trials behind the approved products describe those products, and an unapproved vial sits outside all three.
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA, 15 June 2026
“FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that are falsely labeled "for research purposes" or "not for human consumption." These products have been sold directly to consumers for human use with dosing instructions.”
Checked against the source on 16 July 2026.
Is semaglutide sodium or semaglutide acetate the same drug as the approved semaglutide?: No — FDA's position is that they are a DIFFERENT ACTIVE INGREDIENT, not a lower grade of the same one. FDA received reports that in some cases compounders may be using salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, and stated: 'The salt forms are different active ingredients than is used in the approved drugs, which contain the base form of semaglutide. The FDA is not aware of any basis for compounding using the salt forms that would meet the FD&C Act conditions for types of active ingredients that can be used in compounding.' That distinction is what a vial labelled simply 'semaglutide' hides. If the contents are a salt form, the approval, the prescribing information and the outcome trials behind the approved products are not describing what is in the vial — those studied the base form. FDA has since restated the position in different words, saying it does 'not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug' and is 'not aware of any lawful basis for their use in compounding' — that later wording is on FDA's GLP-1 concerns page, not on the alert quoted here.
FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products — FDA, 26 July 2024
“FDA had also received reports that in some cases, compounders may be using salt forms of semaglutide, including semaglutide sodium and semaglutide acetate. The salt forms are different active ingredients than is used in the approved drugs, which contain the base form of semaglutide. The FDA is not aware of any basis for compounding using the salt forms that would meet the FD&C Act conditions for types of active ingredients that can be used in compounding.”
Checked against the source on 16 July 2026.
Did FDA find that compounded semaglutide doesn't work?: No — FDA never reached that question, and says so explicitly. FDA's clinical-need analysis under section 503B is sequential, and its evaluation of semaglutide stopped at the threshold: 'Because this nomination did not pass through Part 1(a), we did not reach Part 2 and therefore did not consider the Part 2 factors, including the available evidence of effectiveness or lack of effectiveness of a drug product compounded with semaglutide.' What FDA actually evaluated was narrow — whether the nominations identified an attribute of the FDA-approved semaglutide products that makes them medically unsuitable for identified patients, such that a compounded product is needed to address it. It found they did not, and on that basis tentatively found no clinical need and proposed not to include semaglutide on the 503B Bulks List. So FDA's proposal is not a verdict that compounded semaglutide is ineffective, and equally the absence of such a verdict is not evidence that it works. On this record FDA has expressed no view either way.
List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act — FDA, 1 May 2026
“Because this nomination did not pass through Part 1(a), we did not reach Part 2 and therefore did not consider the Part 2 factors, including the available evidence of effectiveness or lack of effectiveness of a drug product compounded with semaglutide.”
Checked against the source on 16 July 2026.
Is compounded semaglutide safe?: Compounded semaglutide is not an FDA-approved drug, which means FDA does not review it for safety, effectiveness or quality before it is marketed, and FDA has published specific documented concerns about it. As of 31 May 2026 FDA had received 990 reports of adverse events associated with compounded semaglutide; FDA notes many of these appear consistent with adverse events seen with the approved products, that causation cannot always be determined, and that because federal law does not require non-outsourcing-facility pharmacies to report adverse events, the true number is likely underreported. Separately, FDA has received reports of adverse events, some requiring hospitalization, that may be related to overdoses from dosing errors with compounded injectable semaglutide, which it attributes to patients measuring and self-administering incorrect amounts and to health care professionals miscalculating — the approved products are pens delivering a preset amount, while compounded products are supplied as vials and syringes. FDA has also reported fraudulent compounded semaglutide whose labels name compounding pharmacies that do not exist. Note the shape of these findings: they concern the product and its presentation, not semaglutide the molecule, whose own labeled risks — including a boxed warning for thyroid C-cell tumors — apply regardless.
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA, 15 June 2026
“This can be risky for patients, as unapproved versions do not undergo FDA's review for safety, effectiveness and quality before they are marketed.”
Checked against the source on 16 July 2026.